<DOC>
	<DOCNO>NCT00890890</DOCNO>
	<brief_summary>The purpose study determine safety tolerability BMS-708163 patient Prodromal Alzheimer 's disease treatment period minimum 104-weeks . In addition patient see safety visit 4 12 week post treatment .</brief_summary>
	<brief_title>A Multicenter , Double Blind , Placebo-Controlled , Safety Tolerability Study BMS-708163 Patients With Prodromal Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient meet clinical criterion prodromal Alzheimer 's disease ( MMSE 2430 ) Memory complaint subject study partner CSF aβ42 level &lt; 200pg/mL Total Tau/aβ42 ratio ≥ 0.39 Score ≤4 Modified Hachinski Ischemia Scale CT result consistent Alzheimer 's disease Medically stable 6 year education Reliable study partner Must able swallow capsule Premenopausal woman DSMIV diagnosis Dementia History stroke Immunocompromised Active peptic ulcer , GI bleed , chronic inflammatory bowel disease , chronic diarrhea past GI surgery would impact drug absorption Unstable Vitamin B12 deficiency Hematologic solid malignancy within 5 year Geriatric Depression Scale ≥ 6 Unstable medical condition Alcohol drug abuse history 12months study entry Significant drug allergy Prisoners , compulsory psychiatric patient , resident nurse home skilled nursing facility entry Any experimental therapy 30days study entry</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>